Cargando…
Three Layers of Personalized Medicine in the Use of Sirolimus and Its Derivatives for the Treatment of Cancer
Rapamycin and its derivatives are mTOR inhibitors which are FDA-approved for use as immunosuppressants and chemotherapeutic agents. These agents are currently approved to treat renal cell carcinomas, soft tissue sarcomas, and other rare tumors. As tumor treatment paradigms are moving away from organ...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219548/ https://www.ncbi.nlm.nih.gov/pubmed/37240915 http://dx.doi.org/10.3390/jpm13050745 |